Source: Beacon Pharmaceuticals PLC (BEACONPHAR) | FY 2011-12 | Page 45

### STATEMENT OF CASH FLOW
For the year ended June 30, 2012

| Particulars | Amount in Taka 30.06.2012 | Amount in Taka 30.06.2011 |
|---|---|---|
| **Cash Flows from Operating Activities:** | | |
| Collection against Sales | 964,534,827 | 692,237,672 |
| Payment to Creditors | (356,300,072) | (365,611,646) |
| Other Operating Expenses | (243,143,528) | (158,452,459) |
| Interest Paid | (212,120,046) | (55,939,413) |
| **Net Cash Generated from Operating Activities** | **152,971,181** | **112,234,154** |
| | | |
| **Cash Flows from Investing Activities:** | | |
| Acquisition of Property, Plant & Equipments | (196,295,211) | (304,746,228) |
| Investment in Shares | - | (233,000,000) |
| Interest and Other Received | 3,505,401 | 52,399,573 |
| Payment to others | (22,555,035) | (27,233,171) |
| **Net Cash Generated from Investing Activities** | **(215,344,845)** | **(512,579,826)** |
| | | |
| **Cash Flows from Financing Activities:** | | |
| Capital Received | - | 300,000,000 |
| Deferred IPO Expense | - | (23,672,153) |
| Excess Share Application Money Received | - | 9,473,420,000 |
| Excess Share Application Money Refund | (111,947) | (9,468,127,058) |
| Long Term Loan Received | - | - |
| Long Term Loan Refund | (54,341,921) | (79,450,000) |
| Short Term Loan Received | 167,111,622 | 686,725,571 |
| Short Term Loan Refund | (64,645,482) | (493,599,283) |
| **Net Cash Generated from Financing Activities:** | **48,012,272** | **395,297,077** |
| Net Cash Increase / (Decrease) | (14,361,392) | (5,048,595) |
| Cash and Bank Balance at the beginning of the year | 21,563,976 | 26,612,571 |
| **Cash and Bank Balance at the end of the year** | **7,202,584** | **21,563,976** |
| | | |
| **Operating Cash flow per Share** | **0.66** | **0.51** |

The annex notes 1 to 29 form an integral part of these financial statements. The financial statements were approved by the Board of Directors as and were signed on its behalf by.